Ovarian, adrenal, and pituitary tumors and drug-induced hirsutism in women should be excluded prior to treatment to ensure the targeting and safety of drug therapy. Hirsutism can be associated with a variety of diseases and medications, such as polycystic ovary syndrome, adrenal tumors, drugs such as phenytoin, etc., so the cause and drug history of the patient should be fully understood before using drug therapy.
For hirsutism caused by different causes, the choice of medication is also different. Oral contraceptives containing estrogen-progestin are a common option for ovarian-derived androgen-overtaking, but they may be associated with side effects such as edema and weight gain.
Long-term use of certain medications may cause other health problems, such as osteoporosis caused by long-term use of glucocorticoids, so they should be used under the guidance of a medical professional and monitored regularly for side effects.
During treatment, if the condition improves or if the medication has serious side effects, the doctor may recommend that the patient stop or change the medication. Patients should follow the doctor's guidance to stop or change the drug and pay attention to the changes in the condition after stopping the drug.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: